Amgen bows out of PhIIb trials testing bispecific, fusion protein for lupus
28 Apr 2023
Phase 2ADCPDC
In a setback to the growing field of systemic lupus erythematosus drug development, Amgen is bowing out of two Phase IIb trials after deciding its candidates were unlikely to work.
Both trials, involving two different molecules, were stopped for futility, Amgen disclosed in its quarterly report. Rozibafusp alfa (AMG 570) is an antibody-peptide conjugate that targets inducible T cell costimulator ligand (ICOSL) and B-cell activating factor (BAFF) in hopes of hitting both immune cell populations; efavaleukin alfa is an interleukin-2 (IL-2) mutein Fc fusion protein.
Preview
Source: EndPoints
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 166,900+ biopharma pros reading Endpoints daily — and it's free.
SIGN UP
LOG IN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.